Lighthouse Financial Advisors Inc. Buys 2,850 Shares of Johnson & Johnson (NYSE:JNJ)

Lighthouse Financial Advisors Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 16.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,000 shares of the company’s stock after purchasing an additional 2,850 shares during the period. Johnson & Johnson makes up 1.6% of Lighthouse Financial Advisors Inc.’s investment portfolio, making the stock its 11th largest holding. Lighthouse Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $2,611,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Houlihan Financial Resource Group Ltd. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $1,376,000. Bowen Hanes & Co. Inc. boosted its stake in shares of Johnson & Johnson by 11.5% during the 4th quarter. Bowen Hanes & Co. Inc. now owns 362,432 shares of the company’s stock valued at $52,868,000 after purchasing an additional 37,290 shares in the last quarter. Community Financial Services Group LLC boosted its stake in shares of Johnson & Johnson by 2.6% during the 4th quarter. Community Financial Services Group LLC now owns 25,571 shares of the company’s stock valued at $3,730,000 after purchasing an additional 645 shares in the last quarter. Chelsea Counsel Co. boosted its stake in Johnson & Johnson by 3.9% during the fourth quarter. Chelsea Counsel Co. now owns 45,344 shares of the company’s stock worth $6,614,000 after acquiring an additional 1,693 shares in the last quarter. Finally, Csenge Advisory Group boosted its stake in Johnson & Johnson by 18.7% during the fourth quarter. Csenge Advisory Group now owns 13,480 shares of the company’s stock worth $1,966,000 after acquiring an additional 2,127 shares in the last quarter. 68.45% of the stock is currently owned by hedge funds and other institutional investors.

JNJ opened at $144.56 on Wednesday. The company has a quick ratio of 1.05, a current ratio of 1.31 and a debt-to-equity ratio of 0.41. The firm has a 50 day moving average price of $147.76 and a 200-day moving average price of $142.57. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The stock has a market capitalization of $380.36 billion, a price-to-earnings ratio of 19.12, a PEG ratio of 3.14 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.27. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The firm had revenue of $20.69 billion during the quarter, compared to analysts’ expectations of $19.48 billion. During the same period in the previous year, the company earned $2.10 earnings per share. The firm’s quarterly revenue was up 3.3% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 7.68 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.79%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Friday, May 22nd. Johnson & Johnson’s payout ratio is presently 46.54%.

In related news, Director William D. Perez acquired 500 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was purchased at an average cost of $127.69 per share, with a total value of $63,845.00. Following the completion of the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.27% of the stock is owned by insiders.

Several research firms recently commented on JNJ. UBS Group lowered shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $163.00 to $160.00 in a research note on Tuesday, April 28th. Credit Suisse Group reissued a “buy” rating and set a $161.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Raymond James boosted their price objective on shares of Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $163.47.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What impact do institutional investors have on markets?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).